Instructions for ATF-Long tablets 10 mg No. 40
Composition
active ingredient:
1 tablet contains ATP-LONG (calculated on a substance that does not contain sodium chloride and water) - 10 mg with a content of 6.3 mg of adenine nucleotides;
excipients: sucrose, lactose monohydrate, corn starch, calcium stearate, sodium benzoate (E 211), colloidal anhydrous silicon dioxide.
Dosage form
Pills.
Main physicochemical properties:
10 mg tablets: white with a flat surface and a bevel.
Pharmacotherapeutic group
Cardiological drugs. ATX code C01E B10.
Pharmacological properties
Pharmacodynamics
ATP-LONG® is a drug of a new class of substances, the molecule of which consists of adenosine-5'-triphosphate (ATP), the amino acid histidine, magnesium and potassium salts, and has a pharmacological effect characteristic only for it, which is not inherent to any of its chemical components.
ATP-LONG® stimulates energy metabolism, normalizes the concentration of potassium and magnesium ions in tissues, improves the antioxidant system of myocardial protection, reduces the concentration of uric acid; has anti-ischemic, membrane-stabilizing, antiarrhythmic effects due to the normalization of metabolic processes in the myocardium during ischemia and hypoxia; improves the indicators of central and peripheral hemodynamics, coronary circulation, increases myocardial contractility, improves the functional state of the left ventricle and increases cardiac output, which increases physical performance, reduces the frequency of angina attacks and shortness of breath during physical exertion. The drug restores normal sinus rhythm in patients with paroxysmal supraventricular and supraventricular tachycardia, with atrial fibrillation and flutter, and also reduces the activity of ectopic rhythm sources (atrial and ventricular extrasystoles).
Pharmacokinetics
After administration into the body, ATP-LONG® slowly breaks down to form adenosine.
Indication
In complex treatment:
coronary heart disease, unstable angina, angina at rest and stress; post-infarction and myocardial cardiosclerosis (diffuse and focal cardiosclerosis); heart rhythm disorders; vegetative-vascular dystonia; myocardial dystrophy; myocarditis; chronic fatigue syndrome.
Used to increase tolerance to physical exertion.
Contraindication
Hypersensitivity to the components of the drug; acute myocardial infarction; cardiogenic and other types of shock; obstructive diseases of the bronchopulmonary system; severe forms of bronchial asthma; sinoatrial blockade II-III degree; atrioventricular (AV) blockade II-III degree; hyperkalemia, hypermagnesemia; hemorrhagic stroke.
Interaction with other medicinal products and other types of interactions
Cardiac glycosides: increased risk of atrioventricular block.
Potassium-sparing diuretics, potassium supplements and ACE inhibitors: increased risk of hyperkalemia.
Magnerot and other magnesium preparations: hypermagnesemia may develop.
Dipyridamole enhances the therapeutic effect of the drug ATF-LONG®.
Xanthinol nicotinate, caffeine, theophylline, aminophylline: reduce the therapeutic effect of the drug ATP-LONG®.
ATP-LONG® may enhance the antianginal effect of alpha- and beta-blockers, calcium channel blockers, and nitrates.
Application features
Use with caution:
with severe arterial hypotension; with cardiac glycosides due to the increased risk of atrioventricular block.
With prolonged use, it is necessary to monitor the level of potassium and magnesium in the blood.
Use with caution in patients prone to bronchospasm.
The drug contains sucrose and lactose, so patients with diabetes should use the drug with caution, and patients with hereditary intolerance to fructose, glucose-galactose, sucrose-isomaltose should not use the drug.
Limit the consumption of products containing caffeine (coffee, tea, cola drinks).
Ability to influence reaction speed when driving vehicles or other mechanisms
If dizziness or low blood pressure occurs during treatment with the drug, you should refrain from driving vehicles and other mechanisms.
Use during pregnancy or breastfeeding
Use in pregnant women is contraindicated.
Breastfeeding should be discontinued during treatment.
Method of administration and doses
ATP-LONG® tablets should be taken under the tongue and kept until completely dissolved. A single dose is 10-40 mg 3-4 times a day, regardless of meals. The duration of treatment is determined by the doctor, on average it is 20-30 days. If necessary, repeat the course after 10-15 days. The maximum daily dose is 160 mg.
Children
Do not use on children.
Overdose
Bradycardia, AV block, hypotension, and syncope may develop.
Treatment: Stop taking the drug and start symptomatic therapy. In case of bradycardia, administer atropine sulfate.
Adverse reactions
Immune system, skin and subcutaneous tissue: allergic reactions, including skin rashes, itching, angioedema, facial flushing.
Respiratory system: bronchospasm.
Cardiovascular system: decreased blood pressure, tachycardia, AV block.
Nervous system: headache, dizziness.
Digestive tract: nausea, feeling of discomfort in the epigastric region, increased gastrointestinal motility.
Urinary system: increased diuresis.
Vessels: sensation of heat.
With prolonged and uncontrolled use - hyperkalemia or hypermagnesemia.
Expiration date
2 years.
Storage conditions
In the original packaging at a temperature of 2 °C to 8 °C.
Keep out of reach of children.
Packaging
10 tablets in a blister, 4 blisters in a pack.
Vacation category
Without a prescription.
Producer
Public Joint Stock Company "Research and Production Center "Borshchagov Chemical and Pharmaceutical Plant".
Location of the manufacturer and its business address
Ukraine, 03134, Kyiv, Myru St., 17.
